Joe Schmitt (Germany)

Cologne University, Germany “Vaccelerate” European Clinical Trial Consortium
As a Professor of infectious diseases and vaccine development Joe has led a national research network on acute respiratory tract infections in children until 2007 and was deeply involved in studies on acellular pertussis-vaccines and their combinations and chaired the German NIITAG (STIKO) over 10 years. He joined industry in 2007 and his last position was Vice President for Medical-, Developmental-, Scientific- and Clinical-Affairs (MDSCA) with Pfizer as Global Lead for Viral Vaccines. Currently, Joe Schmitt is Editor-in-Chief with Global Health Press (GHP) in Singapore and also Strategic and Scientific Advisor with the EU-Commission-funded “Vaccelerate” European Clinical Trial Consortium at Cologne University, Germany.

Author Of 4 Presentations

Welcome

Date
Mon, 09.05.2022
Session Time
15:30 - 17:00
Session Type
Sponsored Symposium
Room
ALEXANDRA TRIANTI HALL
Lecture Time
15:30 - 15:35

Latest clinical data demonstrating the breadth of coverage of MenB-fHbp

Date
Mon, 09.05.2022
Session Time
15:30 - 17:00
Session Type
Sponsored Symposium
Room
ALEXANDRA TRIANTI HALL
Lecture Time
16:23 - 16:37

Conclusions

Date
Mon, 09.05.2022
Session Time
15:30 - 17:00
Session Type
Sponsored Symposium
Room
ALEXANDRA TRIANTI HALL
Lecture Time
16:58 - 17:00

Presenter of 4 Presentations

Latest clinical data demonstrating the breadth of coverage of MenB-fHbp

Date
Mon, 09.05.2022
Session Time
15:30 - 17:00
Session Type
Sponsored Symposium
Room
ALEXANDRA TRIANTI HALL
Lecture Time
16:23 - 16:37

Conclusions

Date
Mon, 09.05.2022
Session Time
15:30 - 17:00
Session Type
Sponsored Symposium
Room
ALEXANDRA TRIANTI HALL
Lecture Time
16:58 - 17:00

Welcome

Date
Mon, 09.05.2022
Session Time
15:30 - 17:00
Session Type
Sponsored Symposium
Room
ALEXANDRA TRIANTI HALL
Lecture Time
15:30 - 15:35

Moderator of 1 Session

Session Type
Sponsored Symposium
Date
Mon, 09.05.2022
Session Time
15:30 - 17:00
Room
ALEXANDRA TRIANTI HALL
Session Description
Broad protection: The fundamental aspect in achieving meningococcal disease control through vaccination – Supported by Pfizer.

Session Description:

The agenda will focus on what we can learn from meningococcal epidemiology and the importance of MenB breadth of coverage and fHbp in protecting against meningococcal disease. The agenda will also include emerging data for the MenB-fHbp vaccine and discuss next steps for controlling meningococcal disease.

Facilitator Of

Session Type
Sponsored Symposium
Date
Mon, 09.05.2022
Session Time
15:30 - 17:00
Room
ALEXANDRA TRIANTI HALL
Session Description
Broad protection: The fundamental aspect in achieving meningococcal disease control through vaccination – Supported by Pfizer.

Session Description:

The agenda will focus on what we can learn from meningococcal epidemiology and the importance of MenB breadth of coverage and fHbp in protecting against meningococcal disease. The agenda will also include emerging data for the MenB-fHbp vaccine and discuss next steps for controlling meningococcal disease.